Pharmacological treatment of painful HIV-associated sensory neuropathy: A systematic review and meta-analysis of randomised controlled trials

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Phillips, Tudor J C ^a   Cherry, Catherine L ^b,c,d   Cox, Sarah ^e   Marshall, Sarah J ^f   Rice, Andrew S C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b BURNET INSTITUTE   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^f EAST KENT HOSPITALS UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; CANNABIS; CAPSAICIN; GABAPENTIN; LAMOTRIGINE; LEVACECARNINE; MEXILETINE; PEPTIDE T; PLACEBO; PREGABALIN; PROSAPTIDE; RECOMBINANT NERVE GROWTH FACTOR; UNCLASSIFIED DRUG; ANTIRETROVIRUS AGENT; NERVE GROWTH FACTOR; PLANT EXTRACT;

ARTICLE; CANNABIS SMOKING; CLINICAL EFFECTIVENESS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; META ANALYSIS; NEUROPATHIC PAIN; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSORY NEUROPATHY; SYSTEMATIC REVIEW; METHODOLOGY; PERIPHERAL NEUROPATHY; REVIEW; RISK; TREATMENT OUTCOME;

CANNABIS;

ANALGESICS; ANTI-RETROVIRAL AGENTS; CANNABIS; CAPSAICIN; HIV INFECTIONS; HUMANS; NERVE GROWTH FACTOR; PERIPHERAL NERVOUS SYSTEM DISEASES; PLACEBOS; PLANT EXTRACTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK; TREATMENT OUTCOME;

EID: 78650828037     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014433     Document Type: Article

References (76)

1. Smyth K, Affandi JS, McArthur JC, Bowtell-Harris C, Mijch AM, et al. (2007) Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006. HIV Med 8: 367-373.
2. Lipkin WI, Parry G, Kiprov D, Abrams D (1985) Inflammatory neuropathy in homosexual men with lymphadenopathy. Neurology 35: 1479-1483.
3. Barohn R, Gronseth G, Leforce B, McVey A, McGuire A, et al. (1993) Peripheral nerve involvement in a large cohort of human immunodeficiency virus-infected individuals. Arch Neurol 50: 167-171.
4. Blum AS, Dal Pan GJ, Feinberg J, Raines C, Mayjo K, et al. (1996) Low-dose zalcitabine-related toxic neuropathy: frequency, natural history, and risk factors. Neurology 46: 999-1003.
5. Yarchoan R, Perno CF, Thomas RV, Klecker RW, Allain JP, et al. (1988) Phase I studies of 29,39-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1: 76-81.
6. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, et al. (2003) Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362: 22-29.
7. Antiretroviral Therapy Cohort Collaboration (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372: 293-299.
8. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, et al. (2007) Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 146: 87-95.
9. Bacellar H, Muñoz A, Miller EN, Cohen BA, Besley D, et al. (1994) Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992. Neurology 44: 1892-1900.
10. Wright E, Brew B, Arayawichanont A, Robertson K, Samintharapanya K, et al. (2008) Neurologic disorders are prevalent in HIV-positive outpatients in the Asia-Pacific region. Neurology 71: 50-56.
11. Konchalard K, Wangphonpattanasiri K (2007) Clinical and electrophysiologic evaluation of peripheral neuropathy in a group of HIV-infected patients in Thailand. J Med Assoc Thai 90: 774-781.
12. Lichtenstein KA, Armon C, Baron A, Moorman AC, Wood KC, et al. (2005) Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis 40: 148-157.
13. Morgello S, Estanislao L, Simpson D, Geraci A, DiRocco A, et al. (2004) HIVassociated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank. Arch Neurol 61: 546-551.
14. Simpson DM, Kitch D, Evans SR, McArthur JC, Asmuth DM, et al. (2006) HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology 66: 1679-1687.
15. UNAIDS JUNPOH (2009) AIDS epidemic update, December 2009. AIDS epidemic update, December 2009. www.unaids.org.
16. Maritz J, Benatar M, Dave JA, Harrison TB, Badri M, et al. (2010) HIV neuropathy in South Africans: frequency, characteristics, and risk factors. Muscle Nerve 41: 599-606.
17. Ellis RJ, Rosario D, Clifford DB, McArthur JC, Simpson D, et al. (2010) Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol 67: 552-558.
18. Finnerup NB, Sindrup SH, Jensen TS (2010) The evidence for pharmacological treatment of neuropathic pain. Pain 150: 573-581.
19. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, et al. (2007) Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132: 237-251.
20. Tan T, Barry P, Reken S, Baker M, Guideline Development Group (2010) Pharmacological management of neuropathic pain in non-specialist settings: summary of NICE guidance. BMJ 340: c1079.
21. Baron R, Tölle TR, Gockel U, Brosz M, Freynhagen R (2009) A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: Differences in demographic data and sensory symptoms. Pain 146: 34-40.
22. Scholz J, Mannion RJ, Hord DE, Griffin RS, Rawal B, et al. (2009) A novel tool for the assessment of pain: validation in low back pain. PLoS Med 6: e1000047.
23. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6: e1000100.
24. Rice ASC, Lever IJ, Zarnegar R (2008) Cannabinoids and analgesia, with special reference to neuropathic pain. In: McQuay HJ, Kalso E, Moore RA, eds. Reviews and Meta-Analyses in Pain. Seattle: IASP Press. 233 p.
25. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
26. Armitage P, Berry G (1990) Statistical methods in medical research. Oxford: Blackwell Scientific Publications.
27. L'Abbé KA, Detsky AS, O'Rourke K (1987) Meta-analysis in clinical research. Ann Intern Med 107: 224-233.
28. Simpson DM, Brown S, Tobias J, NGX-4010 C107 Study Group (2008) Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 70: 2305-2313.
29. Paice JA, Ferrans CE, Lashley FR, Shott S, Vizgirda V, et al. (2000) Topical capsaicin in the management of HIV-associated peripheral neuropathy. J Pain Symptom Manage 19: 45-52.
30. Hahn K, Arendt G, Braun JS, von Giesen HJ, Husstedt IW, et al. (2004) A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol 251: 1260-1266.
31. Simpson DM, McArthur JC, Olney R, Clifford D, So Y, et al. (2003) Lamotrigine for HIV-associated painful sensory neuropathies: a placebocontrolled trial. Neurology 60: 1508-1514.
32. Hart AM, Wilson AD, Montovani C, Smith C, Johnson M, et al. (2004) Acetyl-lcarnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy. AIDS 18: 1549-1560.
33. Osio M, Muscia F, Zampini L, Nascimbene C, Mailland E, et al. (2006) Acetyl-lcarnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study. J Peripher Nerv Syst 11: 72-76.
34. Scarpini E, Sacilotto G, Baron P, Cusini M, Scarlato G (1997) Effect of acetyl-Lcarnitine in the treatment of painful peripheral neuropathies in HIV+ patients. J Peripher Nerv Syst 2: 250-252.
35. Herzmann C, Johnson MA, Youle M (2005) Long-term effect of acetyl-Lcarnitine for antiretroviral toxic neuropathy. HIV Clin Trials 6: 344-350.
36. Youle M, Osio M, ALCAR Study Group (2007) A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Med 8: 241-250.
37. Chiechio S, Copani A, Gereau RW, Nicoletti F (2007) Acetyl-L-carnitine in neuropathic pain: experimental data. CNS Drugs 21 Suppl 1: 31-8; discussion 45-6.
38. Shlay JC, Chaloner K, Max MB, Flaws B, Reichelderfer P, et al. (1998) Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. JAMA 280: 1590-1595.
39. Kieburtz K, Simpson D, Yiannoutsos C, Max MB, Hall CD, et al. (1998) A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Neurology 51: 1682-1688.
40. Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, et al. (2007) Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 68: 515-521.
41. Ellis RJ, Toperoff W, Vaida F, van den Brande G, Gonzales J, et al. (2009) Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 34: 672-680.
42. Woolridge E, Barton S, Samuel J, Osorio J, Dougherty A, et al. (2005) Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage 29: 358-367.
43. Beaulieu P, Ware M (2007) Reassessment of the role of cannabinoids in the management of pain. Curr Opin Anaesthesiol 20: 473-477.
44. Simpson DM, Estanislao L, Brown SJ, Sampson J (2008) An open-label pilot study of high-concentration capsaicin patch in painful HIV neuropathy. J Pain Symptom Manage 35: 299-306.
45. Clifford D, Simpson D, Brown S, Moyle G, Brew B, et al. (2010) A multicenter, randomized, double-blind, controlled study of NGX-4010 (QutenzaH), a high concentration capsaicin patch for the treatment of HIV-associated distal sensory polyneuropathy. 17th Conference on Retroviruses and Opportunistic Infections Feb 16-19th 2010 Abstract #411 - accessible at www.retroconference.org/ 2010/Abstracts/37371.htm.
46. Valdivelu N (1999) Neuropathic pain after anti-HIV gene therapy successfully treated with gabapentin. J Pain Symptom Manage. 1999 Mar;17(3): 155-6. 1999 Mar: 155-156.
47. Newshan G (1998) HIV neuropathy treated with gabapentin. (letter). AIDS 12: 219-221.
48. Gatti, Antonella; Jann, Stefano; Sandro, et al. (1998) Gabapentin in the Treatment of Distal Symmetric Axonopathy in HIV Infected Patients.[Abstract]. Neurology 50: A216.
49. La Spina I, Porazzi D, Maggiolo F, Bottura P, Suter F (2001) Gabapentin in painful HIV-related neuropathy: a report of 19 patients, preliminary observations. Eur J Neurol 8: 71-75.
50. Simpson DM, Schifitto G, Clifford DB, Murphy TK, Durso-De Cruz E, et al. (2010) Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology 74: 413-420.
51. Simpson DM, Olney R, McArthur JC, Khan A, Godbold J, et al. (2000) A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology 54: 2115-2119.
52. Silver M, Blum D, Grainger J, Hammer AE, Quessy S (2007) Double-blind, placebo-controlled trial of lamotrigine in combination with other medications for neuropathic pain. J Pain Symptom Manage 34: 446-454.
53. McArthur JC, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, et al. (2000) A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology 54: 1080-1088.
54. Simpson DM, Dorfman D, Olney RK, McKinley G, Dobkin J, et al. (1996) Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. The Peptide T Neuropathy Study Group. Neurology 47: 1254-1259.
55. Evans SR, Simpson DM, Kitch DW, King A, Clifford DB, et al. (2007) A randomized trial evaluating Prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain. PLoS ONE 2: e551.
56. Rice AS (2008) Should cannabinoids be used as analgesics for neuropathic pain? Nat Clin Pract Neurol 4: 654-655.
57. Dworkin RH, Katz J, Gitlin MJ (2005) Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain. Neurology 65: S7-19.
58. Evans SR, Simpson DM, Kitch DW, King A, Clifford DB, et al. (2007) A randomized trial evaluating Prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain. PLoS ONE 2: e551.
59. Hempenstall K, Nurmikko TJ, Johnson RW, A'Hern RP, Rice AS (2005) Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2: e164.
60. Maratou K, Wallace VC, Hasnie FS, Okuse K, Hosseini R, et al. (2009) Comparison of dorsal root ganglion gene expression in rat models of traumatic and HIV-associated neuropathic pain. Eur J Pain 13: 387-398.
61. Youle M (2007) Acetyl-L-carnitine in HIV-associated antiretroviral toxic neuropathy. CNS Drugs 21 Suppl 1: 25-30; discussion 45-6.
62. Wiffen PJ, Rees J (2007) Lamotrigine for acute and chronic pain. Cochrane Database Syst Rev. pp CD006044.
63. Saarto T, Wiffen PJ (2007) Antidepressants for neuropathic pain. Cochrane Database Syst Rev. pp CD005454.
64. Liu JP, Manheimer E, Yang M (2005) Herbal medicines for treating HIV infection and AIDS. Cochrane Database Syst Rev. pp CD003937.
65. Schifitto G, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, et al. (2001) Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. Neurology 57: 1313-1316.
66. von Gunten CF, Eappen S, Cleary JF, Taylor SG, Moots P, et al. (2007) Flecainide for the treatment of chronic neuropathic pain: a Phase II trial. Palliat Med 21: 667-672.
67. Dorfman D, Dalton A, Khan A, Markarian Y, Scarano A, et al. (1999) Treatment of painful distal sensory polyneuropathy in HIV-infected patients with a topical agent: results of an open-label trial of 5% lidocaine gel. AIDS 13: 1589-1590.
68. King SA (1999) Acupuncture and amitriptyline for HIV-related peripheral neuropathic pain. JAMA 281: 1271-1272.
69. Ulett GA (1999) Acupuncture and amitriptyline for HIV-related peripheral neuropathic pain. JAMA 281: 1270-1; author reply 1271-2.
70. Kaptchuk TJ (1999) Acupuncture and amitriptyline for HIV-related peripheral neuropathic pain. JAMA 281: 1270; author reply 1271-1270; author reply 1272.
71. Bradley WG, Verma A (1996) Painful vasculitic neuropathy in HIV-1 infection: relief of pain with prednisone therapy. Neurology 47: 1446-1451.
72. Phillips KD, Skelton WD, Hand GA (2004) Effect of acupuncture administered in a group setting on pain and subjective peripheral neuropathy in persons with human immunodeficiency virus disease. J Altern Complement Med 10: 449-455.
73. Estanislao L, Carter K, McArthur J, Olney R, Simpson D, Lidoderm-HIV Neuropathy Group (2004) A randomized controlled trial of 5% lidocaine gel for HIV-associated distal symmetric polyneuropathy. J Acquir Immune Defic Syndr 37: 1584-1586.
74. Kemper CA, Kent G, Burton S, Deresinski SC (1998) Mexiletine for HIVinfected patients with painful peripheral neuropathy: a double-blind, placebocontrolled, crossover treatment trial. J Acquir Immune Defic Syndr Hum Retrovirol 19: 367-372.
75. Schifitto G, Yiannoutsos CT, Simpson DM, Marra CM, Singer EJ, et al. (2006) A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy. J Neurovirol 12: 328-331.
76. Navia BA, Dafni U, Simpson D, Tucker T, Singer E, et al. (1998) A phase I/II trial of nimodipine for HIV-related neurologic complications. Neurology 51: 221-228.